Rankings
▼
Calendar
ZTS
Zoetis Inc.
$54B
Q2 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$2.2B
+6.2% YoY
Gross Profit
$1.5B
70.5% margin
Operating Income
$834M
38.3% margin
Net Income
$671M
30.8% margin
EPS (Diluted)
$1.45
QoQ Revenue Growth
+9.0%
Cash Flow
Operating Cash Flow
$183M
Free Cash Flow
$17M
Stock-Based Comp.
$17M
Balance Sheet
Total Assets
$13.7B
Total Liabilities
$9.1B
Stockholders' Equity
$4.6B
Cash & Equivalents
$1.7B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.2B
$2.1B
+6.2%
Gross Profit
$1.5B
$1.4B
+10.5%
Operating Income
$834M
$726M
+14.9%
Net Income
$671M
$529M
+26.8%
Revenue Segments
Dogs and Cats
$1.4B
67%
Cattle
$329M
15%
Swine
$133M
6%
Poultry
$131M
6%
Horses
$65M
3%
Fish
$52M
2%
Geographic Segments
United States Segment
$1.2B
54%
International Segment
$995M
46%
← FY 2023
All Quarters
Q3 2023 →
ZTS Q2 2023 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena